Conditions: Pulmonary Arterial Hypertension Pulmonary Hypertension
Keywords: endothelin receptor antagonist (ETRA) sitaxsentan
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 3
Healthy volunteers: no

Brief summary:
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.

Detailed description:

Arms:
arm 1: Monotherapy arm arm 2: Combination treatment

Interventions: intervention 1: Sitaxsentan intervention 2: Sitaxsentan and Sildenafil
Intervention descriptions: intervention 1: Sitaxsentan = 100 mg tablet administered orally, once daily intervention 2: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day

Protocol document: